PTS202 / Gongwin Biopharm - LARVOL DELTA

Gongxin-KY is tentatively scheduled to be listed in mid-to-late June [Google translation] (Yahoo News) - "According to the current research and development progress...PTS-02, an orphan drug for sexual cancer, is expected to apply for Phase II clinical trials in the third quarter of 2024; PTS100, for the treatment of intermediate and advanced primary liver cancer, is undergoing Phase II clinical patient enrollment at National Taiwan University, Bei Wing, and Beijing Medical University...PTS202 for the treatment of head and neck cancer has completed clinical protocol design."

Clinical protocol • Enrollment status • New P2 trial • Gastrointestinal Cancer • Head and Neck Cancer • Liver Cancer • Oncology • Solid Tumor